<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00001964</url>
  </required_header>
  <id_info>
    <org_study_id>000032</org_study_id>
    <secondary_id>00-H-0032</secondary_id>
    <nct_id>NCT00001964</nct_id>
  </id_info>
  <brief_title>Combination Therapy of Severe Aplastic Anemia</brief_title>
  <official_title>Treatment of Severe Aplastic Anemia With Combined Immunosuppression: Antithymocyte Globulin (ATG) and Cyclosporine A (CSA), and Mycophenolate Mofetil (MMF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the safety and effectiveness of a combination of three drugs in treating&#xD;
      severe aplastic anemia and preventing its recurrence. Two drugs used in this trial ATG and&#xD;
      cyclosporine are standard combination therapy for aplastic anemia. This study will try to&#xD;
      improve this therapy in three ways: 1) by altering the drug regimen to allow the drugs to&#xD;
      work better; 2) by reducing the risk of kidney damage; and 3) by adding a third drug&#xD;
      mycophenolate mofetil to try to prevent disease relapse.&#xD;
&#xD;
      Patients with severe aplastic anemia who do not have a suitable bone marrow donor or who&#xD;
      decline bone marrow transplantation may participate in this study. Patients will have a skin&#xD;
      test for ATG allergy, chest X-ray, blood test, and bone marrow aspiration before treatment&#xD;
      begins. ATG will then be started, infused through a vein continuously for 4 days. Ten days&#xD;
      after ATG is stopped, cyclosporine treatment will begin, taken twice a day by mouth in either&#xD;
      liquid or capsule form and will continue for 6 months. Also, in the first 2 weeks of&#xD;
      treatment, patients will be given a full dose of corticosteroid (prednisone) to prevent serum&#xD;
      sickness that could develop as a side effect of ATG therapy. The dosage will be decreased&#xD;
      after that. Mycophenolate will be started at the same time as ATG, in two daily doses by&#xD;
      mouth, and will continue for 18 months.&#xD;
&#xD;
      Patients will be hospitalized at the beginning of the study. During this time, blood will be&#xD;
      drawn at 3-week intervals and a bone marrow examination will be repeated 3 months after&#xD;
      treatment has begun. Additional tests, including X-rays may be required. After hospital&#xD;
      discharge, patients will be followed on an outpatient basis at 3-month intervals. The&#xD;
      patients own physician will perform blood tests weekly and kidney and liver function tests&#xD;
      every 2 weeks during cyclosporine therapy. Transfusions may be required initially.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe acquired aplastic anemia (SAA) has a poor prognosis if untreated. Bone marrow&#xD;
      transplantation is available to only a minority of patients due to lack of a matched sibling&#xD;
      donor, advanced age of the patient, or cost. Clinical studies at NIH and elsewhere have&#xD;
      demonstrated excellent response rates and improved survival with immunosuppressive&#xD;
      treatments. Laboratory data implicate underlying cytotoxic T-lymphocyte-mediated suppression&#xD;
      of hematopoiesis as the likely proximal cause of disease in most patients. In earlier&#xD;
      clinical protocols we treated SAA with cyclosporine A (CSA) (86-H-0007), antithymocyte&#xD;
      globulin (ATG) (87-H-0124), and combined ATG and CSA (90-H-0146). While intensive&#xD;
      immunosuppression is most effective, relapse is common and some patients also develop second&#xD;
      hematologic complications like myelodysplasia. In this protocol, we modify our regimen by&#xD;
      delaying the introduction of cyclosporine to promote ATG tolerizing effects and adding&#xD;
      mycophenolate mofetil (MMF), a new agent that, like ATG may be relatively specific for&#xD;
      activated lymphocytes, in an effort to reduce the high relapse rate.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 17, 2000</start_date>
  <completion_date type="Actual">May 12, 2015</completion_date>
  <primary_completion_date type="Actual">December 9, 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reduction in 24-month relapse</measure>
    <time_frame>24 months</time_frame>
    <description>reduction in 24-month relapse</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG 40 mg/kg/d for 4 d; CsA 2 weeks after at 12 mg/kg/d for 6 months. MMF starting on first day of ATG at 600 mg/m2 twice daily for 18 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>single arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ATG at 40 mg/kg/day for 4 days; MMF at 600 mg/m2 twice daily for 18 months and CsA at 12 mg/kg/day for 6 months starting 2 weeks after ATG and MMF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>Cyclosporine A</description>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_label>single arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATG</intervention_name>
    <description>ATG</description>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_label>single arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MMF</intervention_name>
    <description>MMF</description>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_label>single arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Only patients with SAA will be admitted, defined as:&#xD;
&#xD;
        Bone marrow cellularity less than 30%.&#xD;
&#xD;
        At least two of the following blood count findings: absolute granulocyte count less than&#xD;
        500/mm(3); platelet count less than 20,000/mm(3); reticulocyte count less than&#xD;
        60,000/mm(3).&#xD;
&#xD;
        Age greater than or equal to 1 years.&#xD;
&#xD;
        Weight greater than 12 kg.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Serum creatinine greater than 2 mg/dl or estimated creatinine clearance less than 40&#xD;
        ml/min.&#xD;
&#xD;
        Underlying carcinoma, recent history of radiation or chemotherapy.&#xD;
&#xD;
        Current pregnancy or unwillingness to be treated with oral contraceptives.&#xD;
&#xD;
        Inability to comprehend the investigational nature of the study.&#xD;
&#xD;
        Moribund status or concurrent hepatic, renal, cardiac, neurologic, or metabolic disease of&#xD;
        such severity that death within 7 to 10 days is likely.&#xD;
&#xD;
        Evidence of other etiology than AA for bone marrow failure, including positive clastogenic&#xD;
        stress cytogenetic assay for Fanconi anemia and marrow chromosome abnormalities typical of&#xD;
        myelodysplasia.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neal S Young, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2000-H-0032.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Young NS. Acquired aplastic anemia. JAMA. 1999 Jul 21;282(3):271-8. doi: 10.1001/jama.282.3.271. No abstract available. Erratum In: JAMA 2000 Jan 5;283(1):57.</citation>
    <PMID>10422997</PMID>
  </reference>
  <reference>
    <citation>Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997 May 8;336(19):1365-72. doi: 10.1056/NEJM199705083361906. No abstract available.</citation>
    <PMID>9134878</PMID>
  </reference>
  <reference>
    <citation>Nimer SD, Ireland P, Meshkinpour A, Frane M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood. 1994 Aug 1;84(3):923-7.</citation>
    <PMID>8043874</PMID>
  </reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 18, 2000</study_first_submitted>
  <study_first_submitted_qc>January 18, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 19, 2000</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematopoiesis</keyword>
  <keyword>Bone Marrow Failure</keyword>
  <keyword>Aplastic Anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

